2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks…
Parkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes in people with Parkinson’s and DLB.
Our two newest pre-clinical research projects
Cure Parkinson’s is pleased to announce the funding for two new projects as part of our annual iLCT Pipeline Research Acceleration Grant Programme.
STEM-PD, a cell-replacement trial for Parkinson’s, releases latest update
The STEM-PD trial has recently released an update, which indicates the team is proceeding to the next trial stage based on early positive safety data.
Clinical trial of lithium in Parkinson’s set to begin
We are delighted to announce funding for an upcoming phase1b clinical trial to investigate whether lithium, a drug currently used to treat mood disorders, could be repurposed to slow down Parkinson’s.